Clinical Trial Update: Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating durvalumab after chemoradiation and as consolidation therapy for stage III non-small cell lung cancer was terminated, with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Rachel Sanborn | Conditions: Lung Cancer, Non-small Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2024-12-20